With the aim to generate improved translational human tauopathy models, we used ZFN technology to introduce the FTDP-17-associated MAPT IVS10+16 and P301S mutations into commercially available control hiPSCs (iPSC0028) from Sigma. The gene discussed is MAPT; the disease is semantic dementia.